Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huperzine A in Alzheimer's Disease
NCT00083590Phase 2Completed
- Sponsor
- National Institute on Aging
- Start
- Apr 2004
- Primary completion
- Nov 2007
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Huperzine A in Alzheimer's disease (AD) (3 arms), sponsored by National Institute on Aging. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 16 weeks. Started Apr 2004; status: completed.
02
Drugs
Huperzine A
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00083590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083590.